Evidence map›Paper›PMID 35268466›Full record

ReviewJournal of clinical medicine2022

The Coexistence of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.

Marcin Kosmalski, Sylwia Ziółkowska, Piotr Czarny, Janusz Szemraj, Tadeusz Pietras

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Investigating the Mechanisms ofFood science & nutrition · 2025
    Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Marcin KosmalskiDepartment of Clinical Pharmacology, Medical University of Lodz, 90-153 Lodz, Poland.ORCID 0000-0003-0609-9657
Sylwia ZiółkowskaDepartment of Medical Biochemistry, Medical University of Lodz, 92-215 Lodz, Poland.
Piotr CzarnyDepartment of Medical Biochemistry, Medical University of Lodz, 92-215 Lodz, Poland.ORCID 0000-0002-5146-5225
Janusz SzemrajDepartment of Medical Biochemistry, Medical University of Lodz, 92-215 Lodz, Poland.ORCID 0000-0001-6052-3557
Tadeusz PietrasDepartment of Clinical Pharmacology, Medical University of Lodz, 90-153 Lodz, Poland.
Medical University of Lodz · PL

Funding

Medical University of Lodz 503/1-151-07/503-11-001-18Medical University of Lodz 503/6-086-01/503-61-001-19-00.
6 · The paper itself

Abstract

The incidence of nonalcoholic fatty liver disease (NAFLD) is growing worldwide. Epidemiological data suggest a strong relationship between NAFLD and T2DM. This is associated with common risk factors and pathogenesis, where obesity, insulin resistance and dyslipidemia play pivotal roles. Expanding knowledge on the coexistence of NAFLD and T2DM could not only protect against liver damage and glucotoxicity, but may also theoretically prevent the subsequent occurrence of other diseases, such as cancer and cardiovascular disorders, as well as influence morbidity and mortality rates. In everyday clinical practice, underestimation of this problem is still observed. NAFLD is not looked for in T2DM patients; on the contrary, diagnosis for glucose metabolism disturbances is usually not performed in patients with NAFLD. However, simple and cost-effective methods of detection of fatty liver in T2DM patients are still needed, especially in outpatient settings. The treatment of NAFLD, especially where it coexists with T2DM, consists mainly of lifestyle modification. It is also suggested that some drugs, including hypoglycemic agents, may be used to treat NAFLD. Therefore, the aim of this review is to detail current knowledge of NAFLD and T2DM comorbidity, its prevalence, common pathogenesis, diagnostic procedures, complications and treatment, with special attention to outpatient clinics.

Indexed as

diagnosisepidemiologyinsulin resistancemetabolic syndromenonalcoholic fatty liver diseaseobesitytreatmenttype 2 diabetes mellitus

Identifiers

PMID35268466
PMCPMC8910939
OpenAlexW4214895759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.